SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Case based debate: Is HCC increased with DAA therapy? Con stance- Nicolás Merchante, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017The use of HIV+ or HCV+ organs in transplantation- Stefano Fagiuoli, MDView Slideset
MPMarion PetersMDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Non liver and survival benefits of SVR in HCV - Marion Peters, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Direct acting antiviral treatment for HCV in safety net settings: Provider and HIV/HCV co-infected patient preferences- M. PetersView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Outbreak of hepatitis A in men who have sex with men in 2017 - Experience in an infectious diseases department, Hospital de Curry Cabral - CHLC, Lisbon, Portugal- A.R. GarroteView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Acute hepatitis A outbreak among men who have sex with men in Milan: the role of HIV co-infection- M. MerliView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unravelled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort - L. CuypersView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)- P. Rodriguez CortesView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1- P. BuggishView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. SeixasView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?- R. ValenteView Slideset
DDDouglas DieterichMDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on HIV & Hepatitis Co-infection 2017Are there any special populations in treatment of HCV left?- Douglas Dieterich, MDView Slideset
